Global Short Bowel Syndrome Market (Drug Type - GLP-2, Glutamine, Growth Hormone and Other Drugs) by Distribution channel (Hospital Pharmacies, Retail Pharmacies & others) and by Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and Latin America) Opportunity Analysis, Trends, and Forecasts (2019 2028).
- Published Date: 2022-12-26
- Report ID: 138116
- Pages: 200
-
Format:
Report Overview
The global short bowel syndrome was valued at US$ 612Mn in 2019 and is projected to expand at a CAGR of 27% from 2019 to2028.
The major factors attributing to the growth of the SBS market are rise in global prevalence of GI disorders like volvulus, Inflammatory bowel disease (IBD), in particular, Crohns disease (CD), which predisposes patients to development of SBS and mesenteric ischemia are the most common causes for SBS among all the age groups which demand the necessity of the treatment.
Additionally, the increased awareness programs led by several associations like the Association of gastrointestinal motility, Oley Foundation and the SBS Cure Project coupled with rising in the government health care expenditure are likely to drive the market growth over the forecast period.
Market Drivers
The major factors attributing to the growth of the SBS market are rise in global prevalence of GI disorders like volvulus, Inflammatory bowel disease (IBD), in particular, Crohns disease (CD), which predisposes patients to development of SBS and mesenteric ischemia are the most common causes for SBS among all the age groups which demand the necessity of the treatment.
1. Global Short Bowel Syndrome Market Overview..........................
A. Market Size
2. Market Growth Drivers...
A. Increased Prevalence of Short Bowel Syndrome and Awareness Programs by Non-Profit Organizations
B. Rising Efforts in the Launch of Effective Treatments and Awareness Programs by Non-Profit Organizations
3. Market Restraints.......
A. Lack of Availability of the Approved Drugs in Developing Countries
B. Lethal Adverse Complications like Colonic Cancer, Polyps along with Common Side Effects Associated with the Medication
4. Short Bowel Syndrome Market Segmentation.....................
A. By Drug Class
I. GLP-2
II. Growth Hormone
III. Glutamine
IV. Others
B. Pain Type
I. Acute Pain
II. Chronic Pain
C. By Distribution Channel
I. Hospital Pharmacies
II. Retail Pharmacies
III. Others
D. By Geography
I. North America Market Analysis
II. Europe Market Analysis
III. Asia-Pacific Market Analysis
IV. Latin America, Middle-East and Africa Market Analysis
5. Short Bowel Syndrome Major Drugs Market Share....
A. Market Analysis, Insights and Forecast by revenue
6. Competitive Landscape......
A. Major Players
B. Products in Pipeline
7. Key Company Profiles....
A. Takeda Company overview, Product & Services, Strategies & Financials
B. Nutrinia Company overview, Product & Services, Strategies & Financials
C. OxThera Company, Product & Services, Strategies & Financials
8. Potential Growth Opportunities.....
A. Advancements in drug development
B. Untapped markets in developing economies
9. Factors Driving Future Growth..
A. Key Industry Developments of Short Bowel Syndrome Market
B. Future Opportunities
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
